Divi's Laboratories Limited has fixed July 24, 2026, as the record date to determine shareholder eligibility for a dividend of ₹30 per equity share for the financial year 2025-26. The Board of Directors recommended this payout at its meeting on May 23, 2026, subject to shareholder approval at the upcoming Annual General Meeting. The dividend of ₹30 per share on a face value of ₹2 each translates to 1,500%. If approved, payment will commence on or from August 14, 2026, subject to tax deduction at source.

The 36th Annual General Meeting is scheduled for Monday, August 10, 2026, at 10:00 A.M. IST. The meeting will be conducted through Video Conferencing (VC) and Other Audio-Visual Means (OAVM) in compliance with relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Notice of the AGM along with the Annual Report 2025-26 will be sent electronically to members and will also be available on the company's website.

Shareholders are required to ensure compliance with Know Your Customer (KYC) norms to receive dividends. Payments will be processed exclusively in electronic mode. Members holding shares in physical form must ensure their folios are KYC compliant by registering PAN, contact details, bank account details, and specimen signatures with the company or its Registrar and Transfer Agent, KFin Technologies Limited. Failure to meet these requirements will result in an inability to receive the dividend.

The company has informed shareholders that dividend income is taxable in their hands under the Income Tax Act, 2025. Consequently, tax will be deducted at source at the prescribed rates. Shareholders have been requested to submit applicable declarations and documents on or before July 24, 2026. A communication regarding tax deduction was sent via email on June 10, 2026, and is available on the company's website.

Key AGM and Dividend Details

Divi's Laboratories Limited disclosed on April 06, 2026, that its promoter group has not encumbered any shares during the financial year ended March 31, 2026. The declaration, submitted to the National Stock Exchange of India and BSE Limited, confirms that no shares were pledged directly or indirectly by the promoters or Persons Acting in Concert (PAC). This disclosure is significant for shareholders as it indicates the absence of leverage risk against the promoter holding, which accounts for over half of the company's total equity.

The filing was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Dr. Murali K. Divi, Promoter and Managing Director, signed the disclosure on behalf of the promoter group. The statement covers the promoter group's entire shareholding, ensuring transparency regarding the ownership status of the key stakeholders in the company.

The promoter group, including Dr. Murali K. Divi and other PAC members, collectively holds 13,75,67,000 equity shares. This represents 51.82% of the company's total share capital and total diluted share capital. The largest individual holdings within the group are attributed to Dr. Kiran Satchandra Divi and Nilima Prasad Divi, each holding 20.34% of the total share capital.

The following table details the shareholding pattern of the promoter group as disclosed in the filing:

The confirmation of no encumbrance provides stability to the shareholding structure of Divis Laboratories . The document was signed in Hyderabad on April 06, 2026, and a copy was forwarded to the Audit Committee of the company for its records.